Anika Therapeutics (ANIK) Net Cash Flow (2010 - 2026)

Anika Therapeutics (ANIK) has reported Net Cash Flow for 17 consecutive years, with -$2.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Net Cash Flow fell 385.43% year-over-year to -$2.7 million; the TTM figure through Jun 2026 stood at -$14.4 million (down 39.76% YoY), while the FY2025 annual figure was $236000.0, up 101.51% from the prior year.
• Net Cash Flow grew to -$2.7 million in Q2 2026 per ANIK's latest filing, from -$16.4 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $5.6 million in Q3 2023 and bottomed at -$16.4 million in Q1 2026.
• Historically, Net Cash Flow has averaged -$3.1 million across 5 years, with a median of -$3.1 million in 2022.
• Annual changes were most pronounced in 2023 — Net Cash Flow slumped 1433.3% — and 2025, when it surged 747.91%.
• Anika Therapeutics' Net Cash Flow stood at -$1.4 million in 2022, then surged by 254.96% to $2.1 million in 2023, then plunged by 337.34% to -$5.1 million in 2024, then surged by 91.26% to -$444000.0 in 2025, then sank by 500.23% to -$2.7 million in 2026.
• Business Quant data shows ANIK's Net Cash Flow at -$2.7 million in Q2 2026, -$16.4 million in Q1 2026, and -$444000.0 in Q4 2025.